IL6 and COVID-19: Orosomucoid is known to be regulated by TNF-β, IL1β, IL6 and IL6-related cytokines (Baumann et al., 1989; Fournier et al., 2000), along with immunomodulating effects like inhibiting neutrophil migration (Mestriner et al., 2007), and has been employed as a biomarker in COVID-19 (Shu et al., 2020).